Suchergebnisse - "Spiekermann, Karsten"

PubPharm (17)

1

Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia : A Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Bornhäuser, M. | Schliemann, C. | Schetelig, J. | +26

2

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy

enthalten in: Annals of hematology | 2023

von Berdel, A. | Koch, R. | Gerss, J. | +15

3

Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia

enthalten in: Leukemia | 2020

von Bamopoulos, S. | Batcha, A. | Jurinovic, V. | +21

4

Imatinib dose reduction in major molecular response of chronic myeloid leukemia : results from the German Chronic Myeloid Leukemia-Study IV

enthalten in: Haematologica | 2019

von Michel, C. | Burchert, A. | Hochhaus, A. | +58

CommentIn: Haematologica. 2019 May;104(5):862-864. - PMID 31040230

5

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study

enthalten in: Leukemia | 2018

von Braess, J. | Amler, S. | Kreuzer, K. | +43

6

Genetics of acute myeloid leukemia in the elderly : mutation spectrum and clinical impact in intensively treated patients aged 75 years or older

enthalten in: Haematologica | 2018

von Prassek, V. | Rothenberg-Thurley, M. | Sauerland, M. | +16

CommentIn: Haematologica. 2018 Nov;103(11):1758-1759. - PMID 30381416

7

Frontline therapy of acute promyelocytic leukemia : Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines

enthalten in: European journal of haematology | 2018

von Lengfelder, E. | Görlich, D. | Nowak, D. | +21

8

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

enthalten in: Blood | 2016

von Metzeler, K. | Herold, T. | Rothenberg-Thurley, M. | +23

9

Long-term follow-up of cytogenetically normal CEBPA-mutated AML

enthalten in: Journal of hematology & oncology | 2014

von Pastore, F. | Kling, D. | Hoster, E. | +10

10

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

enthalten in: Haematologica | 2014

von Hanfstein, B. | Lauseker, M. | Hehlmann, R. | +27